Selective ER degraders/downregulators (SERDs) have been developed to overcome endocrine resistance, particularly in ESR1-mutant breast cancers [113, 114], which results in the constitutive activation of ER and reduced sensitivity to standard oestrogen therapies (ETs) [113, 127]. Here, ESR1 is linked to breast carcinoma.